Ind-Swift Laboratories Ltd. reported record results for the quarter ended September 2026.

Net sales reached a record ₹240.46 crores. Operating profit (PBDIT) hit a record ₹45.46 crores. Profit after tax (PAT) reached a record ₹34.68 crores.

The performance reflected robust operational execution and favorable market conditions for the company’s products. MarketsMojo upgraded its rating on the company from Sell to Hold.

The stock has outperformed the Sensex across multiple time frames and is trading near its 52-week high. Ind-Swift Laboratories operates in the micro-cap pharmaceutical sector.